NCT06593314 Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes
| NCT ID | NCT06593314 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Texas Southwestern Medical Center |
| Condition | Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 800 participants |
| Start Date | 2025-08-06 |
| Primary Completion | 2026-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 800 participants in total. It began in 2025-08-06 with a primary completion date of 2026-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A pragmatic electronic health record (EHR) based randomized controlled trial to evaluate the utility of providing Ultromics EchoGo analysis results and recommendations for HF risk prevention therapies using an EHR embedded clinical decision support tool.
Eligibility Criteria
Clinical cohort inclusion exclusion criteria: Inclusion Criteria: * Patients with diagnosis of Type 2 diabetes and High WATCH DM score. * Echocardiogram available in last 6-months. Exclusion Criteria: * History of HF * Not eligible for prescription of new GLP-1RA or SGLT2i or ns-MRA Corresponding providers to patients identified by the above inclusion exclusion criteria will be included in the clinical trial of the decision support tool.
Contact & Investigator
Ambarish Pandey, MD
PRINCIPAL INVESTIGATOR
University of Texas Southwestern Medical Center
Frequently Asked Questions
Who can join the NCT06593314 clinical trial?
This trial is open to participants of all sexes, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06593314 currently recruiting?
Yes, NCT06593314 is actively recruiting participants. Contact the research team at Ambarish.Pandey@UTSouthwestern.edu for enrollment information.
Where is the NCT06593314 trial being conducted?
This trial is being conducted at Dallas, United States.
Who is sponsoring the NCT06593314 clinical trial?
NCT06593314 is sponsored by University of Texas Southwestern Medical Center. The principal investigator is Ambarish Pandey, MD at University of Texas Southwestern Medical Center. The trial plans to enroll 800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.